Molecular markers in breast cancer: Can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors?

Breast

Volumn 11, Issue 4, 2002, Pages 279-285

  Dimitrakakis, Constantine ^a,b   Konstadoulakis, Manousos ^a   Messaris, Evangelos ^a   Kymionis, George ^a   Karayannis, Maria ^a   Panoussopoulos, Dimitrios ^a   Michalas, Stylianos ^b   Androulakis, George ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; ONCOPROTEIN; PARAFFIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ACCURACY; ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CENTER; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GREECE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL SCHOOL; ONCOGENE C ERB; ONCOLOGICAL PARAMETERS; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 0036700574     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2002.0445     Document Type: Article

References (36)

1. McGuire W L, Clark G. Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992; 326: 1756.
2. Riou G, Mathieu M C, Barrois M, Le Bihan M L, Ahomadegbe J C, Benard J, Le M G. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein overexpression in operable breast-cancer patients. Int J Cancer 2001 20; 95(4): 266-270.
3. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of Her-2 oncoprotein expression in breast cancer: a 30-year follow up. J Clin Oncol 1992; 10: 1044.
4. Thor A D, Moore D H II, Edgerton S M, Kawasaki E S, Reihsaus E, Lynch H T, Marcus J N, Schwartz L, Chen L C, Mayall B H et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845.
5. Bucci B, Carico E, Rinaldi A, Froio F, Puce Y M, D'Agnano I, Vecchione A, Brunetti E. Biological indicators of aggressiveness in T1 ductal invasive breast cancer. Anticancer Res 2001; 21(4B): 2949-2955.
6. Rochaix P, Krajewski S, Reed J C, Bonnet F, Voigt J J, Brousset P. In vivo patterns of bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol 1999; 187: 410.
7. Muss H B, Thor A D, Berry D A, Kute T, Liu E T, Koerner F, Cirrincione, C T, Budman D R, Wood W C, Barcos M, Henderson I C. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260.
8. Cox D R. Regression models and life table. J R Stat Soc B 1972; 34: 187.
9. Bland K, Konstadoulakis M M, Vezeridis M, Wanebo H. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995; 221: 706.
10. Tomlinson I P, Bodmer W F. Failure of programmed cell death and differentiation as causes of tumors: some simple mathematical models. Proc Natl Acad Sci USA 1995; 92(24): 11130.
11. Ikeguchi M, Maeta M, Kaibara N. Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer. Int J Mol Med 2001; 7(4): 413-417.
12. Munster P N, Norton L. Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res 2001; 3(6): 361-364.
13. Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDRI and LRP. Anticancer Res 2000; 20(6B): 4373-4377.
14. Harris L N, Yang L, Liotcheva V, Pauli S, Iglehart J D, Colvin O M, Hsieh T S. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7(6): 1497-1504.
15. Ludwig R L., Bates S, Vousden K H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16(9): 4952.
16. Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996; 16(9): 4961.
17. Tandon A K, Clark G M, Chamnes G C, Ullrich A, McGuire W L. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120.
18. Gusterson B A, Gullic W J, Venter D J. Immunohistochemical localization of c-erbB-2 in human breast carcinomas. Mol Cell Probes 1988; 1: 383.
19. De Jong D, Prins F, Mason D, Reed J, Van Ommen G, Kluin P. Subcellular localization of bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 1994; 54: 256.
20. Kapranos N, Karaiosifidi H, Valavanis C, Kouri E, Vasilaros S. Prognostic significance of apoptosis related proteins bcl-2 and bax in node negative breast cancer patients. Anticancer Res 1997; 17: 2499.
21. Horak E, Smith K, Bromley L, LeJeune S, Greenall M, Lane D, Harris A L. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 1991; 6(12): 2277.
22. Varley J M, Brammar W J, Lane D P, Swallow J E, Dolan C, Walker R A. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991; 6(3): 413.
23. Sturm I, Papadopoulos S, Hillebrand T, Benter T, Luck H J, Wolff G, Dorken B, Daniel P T. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer 2000 15; 87(4): 517-521.
24. Marks J R, Humphrey P A, Wu K, Berry D, Bandarenko N, Kerns B J M, Iglehart J D. Overexpression of p53 and Her-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994; 219(4): 332.
25. Lehr H A, Jacobs T W, Yaziji H, Schnitt S J, Gown A M. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol 2001; 115(6): 814-822.
26. O'Malley F P, Parkes R, Latta E, Tjan S, Zadro T, Mueller R, Arneson N, Blackstein M, Andrulis I. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 2001; 115(4): 504-511.
27. Silvestrini R, Veneroni S, Daidone M G, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Nad Cancer I 1994; 86: 499.
28. Hurliman J, Larrinaga B, Vala D. Bel-2 protein in invasive ductal breast carcinomas. Virchows Archiv 1995; 426: 163.
29. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 Protein and long term survival in breast cancer. Am J Pathol 1994; 145: 1191.
30. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V M, Niskanen E, Nordling S, Reed J C. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471.
31. Bargou R C, Wagener C, Bommert K, Mapara M Y, Daniel P T, Arnold W, Dietel M, Guski H, Feller A, Royer H D, Dorken B. Overexpression of the deat promoting gene bax - a, which is downregulated in breast cancer restores sensistivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 1996; 97: 2651.
32. Kapucuoglu N, Losi L, Eusebi V. Immunohistochemical localization of bcl-2 and bax proteins in situ and invasive duct breast carcinomas. Virchows Arch 1997; 430: 17.
33. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erb2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462.
34. Rudolph P, Olsson H, Bonatz G, Ratien V, Bolte H, Baldetorp B, Ferno M, Parwaresch R, Alm P. Correlation between p53, c-erb-2 and topoisomerase Iia expression, DNA ploidy, hormonal receptor status and proliferation in 356 node negative breast carcinomas: prognostic implications. J Pathol 1999; 187: 207.
35. Pharoah P D P, Day N E, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta analysis. Br J Cancer 1999; 80: 1668.
36. Horne G M, Anderson J J, Tiniakos D G et al. p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 1996; 73: 29-35.